SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing heightened investor attention as the market rotates into quantum computing stocks, buoyed by significant industry partnerships with NVIDIA and active government contracts for space and defense applications. The community is actively discussing the stock's potential for a valuation re-rating, highlighting its neutral-atom technology and institutional interest as key drivers for long-term growth versus shorter-term momentum peers.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors rally around the company's confirmed control of 92.5% of the Tanbreez rare earth project following final regulatory approval from Greenland. The community is focused on the stock's potential as a strategic play for Western supply chain independence and is actively debating whether current momentum will lead to a sustained breakout or a near-term consolidation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following a post-earnings sell-off where investors reacted negatively to weak forward guidance and the departure of co-founder Reed Hastings from the board, despite the company posting strong quarterly revenue and profit figures. While many retail participants are framing the price drop as a "no-brainer" buying opportunity and actively loading up on dips, others are debating whether the stock is undergoing a structural narrative shift or simply experiencing a temporary liquidity reset after a strong pre-earnings run.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and significant debate as investors react to the company's aggressive Bitcoin acquisition strategy and its correlation with crypto market movements. Community sentiment is deeply divided between bulls betting on a massive short squeeze driven by institutional accumulation, and skeptics who are raising concerns over the sustainability of its debt-funded business model.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is currently trending as investors focus on the potential of its CAN-2409 immunotherapy platform and upcoming data presentations for prostate and lung cancer. The community is actively discussing the company's regulatory progress, recent insider accumulation, and the potential for a significant valuation re-rating ahead of expected BLA filings.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors monitor potential legislative progress with the Clarity Act and celebrate new integration partnerships in international markets like Japan and Korea. The community remains highly polarized, with some debating the token's long-term utility as a bridge currency while others express frustration over stagnant price action and past regulatory hurdles.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating buzz as investors speculate on a major breakout, with the community closely tracking its performance against Bitcoin and watching for potential catalysts like upcoming X integration and social media influence. While some participants are actively accumulating in anticipation of a parabolic move, others remain skeptical, leading to intense debate over the coin's long-term utility versus its role as a high-volatility meme asset.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. (ASST) is trending as investors react to aggressive institutional accumulation and the companys ongoing strategy of utilizing digital credit to increase its Bitcoin treasury holdings. Community sentiment remains polarized, with bulls focused on the potential for long-term growth as a Bitcoin proxy, while critics remain vocal about the stock's history of dilution and the impact of previous reverse splits.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility driven by reports of an anticipated executive order from the White House supporting research into ibogaine for PTSD treatment. While some community members are betting on a massive short squeeze due to the stock's low float and high speculative interest, others are warning of dilution risks and past patterns of aggressive selling, leading to intense debate among traders regarding the sustainability of the current price action.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently capturing significant attention as investors speculate on a broader nuclear sector rally, fueled by a positive mandate from the White House regarding space-based nuclear energy and an ongoing institutional board reorganization. The community remains deeply divided, balancing excitement over potential long-term commercial milestones like Aurora reactor criticality against skepticism regarding the company's lack of current revenue and the heavy volume of insider share sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results

Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; analysts maintain Buy ratings.read more...

<ul class="summary-bullets"><li>The treatment showed an objective response rate of 44% and a disease control rate of 94%.</li><li>Kura said tumor shrinkage was seen in 75% of the 16 patients on trial.</li><li>The results were presented at the International Kidney Cancer Symposium Europe 2026 in Paris.</li></ul>Shares of Kura Oncology (KURA) jumped more than 13% in pre-market trading on Friday after the clinical-stage biotech firm reported encouraging early data from its ongoing trial for the treatment of advanced kidney cancer.The results, presented at the International Kidney Cancer Symposium Europe 2026 in Paris, focused on patients with clear cell renal cell carcinoma (ccRCC).If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/KURA">KURA shares</a> would hit their highest levels since Jan. 7, 2026.<h2 class="st-heading-2">Strong Response Rates, But Small Sample Size</h2>Kura shared initial results from an ongoing FIT-001 trial testing its investigational therapy, Darlifarnib, in combination with Cabozantinib, a type of target enzyme inhibitor, in kidney cancer patients who had already been treated with Cabozantinib.The treatment showed an objective response rate of 44% and a disease control rate of 94%. Tumor shrinkage was seen in 75% of patients, including those who had previously shown limited response to Cabozantinib.Of the 16 patients receiving treatment over an 8- to 56-week period, six are still receiving therapy at the time of the analysis, the company said.<h2 class="st-heading-2">What Investors Should Watch Next</h2>The treatment also demonstrated a manageable safety profile across different dose levels. The study is testing Darlifarnib at daily doses of 3 mg, 5 mg, or 8 mg, taken in cycles of 7 days on and 7 days off, along with daily Cabozantinib at 60 mg or 40 mg. All patients in the study have previously received immunotherapy.The study is now advancing into Phase 1b to further evaluate the optimal dosing and potential benefits of the regimen.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the run-up to start soon.<stembedurl>https://stocktwits.com/mulc/message/650490176</stembedurl>Another user expects “positive news” from the company’s conference call.<stembedurl>https://stocktwits.com/Georgeson/message/650542576</stembedurl>Year-to-date, the stock has shed around 15%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

KURA Stock Pops After Promising Early Cancer Data — What Investors Should Know

The biotech firm reported encouraging early data from its ongoing trial for advanced kidney cancer.

Why Did KURA Stock Jump 13% In Pre-Market Today?

Equity

Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lake Street Capital

Lake Street Capital upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday...

Kura Oncology (NASDAQ:KURA) Trading Up 4.8%  - Here's What Happened

Kura Oncology (NASDAQ:KURA) Stock Price Up 4.8% - Should You Buy...

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume  - Time to Buy?

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume - Should You Buy...

Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation...

Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00

Mizuho decreased their price target on shares of Kura Oncology from $30.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday...

Implied Volatility Surging for Kura Oncology Stock Options

Investors need to pay close attention to Kura Oncology stock based on the movements in the options market lately.

FY2027 EPS Forecast for Kura Oncology Lowered by Analyst

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Stock analysts at Brookline Capital Acquisition dropped their FY2027 earnings estimates for Kura Oncology in a note issued to investors on Thursday...

Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush

Wedbush reduced their price target on Kura Oncology from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Friday...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Current Price	$9.59
Prev Close	$8.94
Open	$9.50
Dividend Yield	0.00%
50-Day Moving Average	$8.48
Beta	1.05
Avg. Volume	1.53M
PE Ratio	-2.81

52-Week High	$12.49
52-Week Low	$5.45
Market Capitalization	$789.67M
EPS (Annual)	-$3.18
Price to Book	4.51
Revenue Per Employee	$259,546.15

KURA
Kura Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News

KURAKura Oncology Inc